Extracorporeal Membrane Oxygenation Systems Market Outlook (2022-2033)

Increasing Prevalence of Severe Cardiopulmonary Conditions

The increase in severe cardiopulmonary diseases requiring advanced life support has been the most important driver for the Extracorporeal Membrane Oxygenation (ECMO) Systems Market. Globally, there is an increase in the incidence of diseases such as: Acute Respiratory Distress Syndrome (ARDS), Heart Failure (HF), Chronic obstructive Pulmonary Disease (COPD), or Cardiac Complications due to Surgeries or Trauma, where the presence of these diseases mean that the patient must be treated with advanced Life Support - ECMO. The COVID-19 Pandemic was one of the main factors in increasing demand for ECMO, as the increase in patients with Severe Respiratory Failure resulted in a greater need to utilize/clinical reliance on ECMO. The increasing prevalence of the older population (Geriatric) population as well as the greater numbers of patients who survive complex cardiac surgeries, are also factors contributing to the increase in the patient population requiring ECMO. Increased awareness on the part of healthcare providers regarding the use of ECMO as either Bridge-to-Recovery or Bridge-to-Transplant has also been a key contributor to the establishment of additional ECMO programs in nations around the world. In addition, major advances in ECMO technologies have made these systems safer, easier to use, and therefore, have increased utilization within Intensive Care Units (ICUs). Thus, the rising burden of severe cardiopulmonary diseases continues to play a major role in enhancing the growth of the Global ECMO Systems Market.

Expansion into Portable and Mobile ECMO Applications

The ECMO systems market is expected to experience growth opportunity with the creation and implementation of portable, mobile and transportable ECMO equipment. The traditional sources of ECMO equipment were large and complex and were initially exclusively utilized within a hospital’s intensive care unit (ICU). However, advancements in technology have made it possible for ECMO devices to be smaller, lighter and user-friendly and used out of the hospital environment. As a result, critical care providers are now able to perform ECMO during transport to and from hospitals, during emergency transfer of patients in out-of-hospital settings, and in locations with limited access to resources. Furthermore, the ability to provide ECMO therapy while patients are being transported is essential for patients who are in urgent need of being sent to specialized centres for advanced care or transplantation. Additionally, portable ECMO devices will allow for the broader use of ECMO in smaller hospitals and clinics that do not have dedicated ECMO service capabilities, thereby enhancing patient access to this lifesaving technology. As Emergency Medical Services (EMS) and Critical Care networks continue to change, demand for mobile ECMO equipment will increase substantially. The movement toward a more mobile ECMO market not only improves patient survival, but also creates new markets and ways to utilize ECMO technology, facilitating long-term growth opportunities for manufacturers of ECMO products. The development of portable ECMO technologies, therefore, represents an opportunity for ECMO manufacturers to expand their reach and meet the unmet clinical needs of patients globally.

The "Extracorporeal Membrane Oxygenation Systems Market Size and Forecast (2022 - 2033)" report provides a detailed analysis of the market covering below areas:

• Extracorporeal Membrane Oxygenation Systems market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Extracorporeal Membrane Oxygenation Systems market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Extracorporeal Membrane Oxygenation Systems market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Extracorporeal Membrane Oxygenation Systems market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Extracorporeal Membrane Oxygenation Systems market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. The Extracorporeal Membrane Oxygenation Systems market in Asia Pacific is expected to grow significantly during the forecast period.

The Asia-Pacific Extracorporeal Membrane Oxygenation Systems market is segmented into China, Japan, South Korea, India, Australia, New Zealand, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Taiwan, Bangladesh, and the Rest of Asia. The continued growth of investments into, the healthcare segment, along with the increasing occurrence of cardiopulmonary disease, and growing number of critical care facilities, has allowed the ECMO system market to continue growing exponentially in this area. Countries such as China, India, Japan, South Korea, and Australia are experiencing a rise in urbanization, a change in lifestyle, and an increase in the occurrence of chronic respiratory or cardiac conditions (acute respiratory distress syndrome, heart failure, chronic obstructive pulmonary disease), leading to an increased need for complex life-support systems.

The worldwide COVID-19 pandemic acted as a rapid reinforcement for the advancements in expanded understanding and acceptance of ECMO systems, as the awareness of ECMO's lifesaving potential for severe respiratory failure patients improved. With the investment of governments and private healthcare entities into the expansion and availability of intensive care facilities, through both the development of new facilities, along with the ongoing training of professionals and the procurement of advanced ECMO systems, there was an increase in ECMO system adoption within the major metropolitan areas. Additionally, due to the improvements being made to the reimbursement policies in addition to increasing patient affordability there has been an influx of ECMO system therapy into the overall healthcare environment.

Additionally, recent developments in portable and user-friendly ECMO devices are helping to reduce infrastructure obstacles and make them more accessible to hospitals located in outlying areas or smaller cities. Additionally, as a result of the expanding digital health ecosystem & telemedicine initiatives, remote training and expert consultations now exist to help drive market development as well. The combination of these factors will create a positive marketplace environment for the growth of ECMO systems in the Asia Pacific region, with clinical requirements being a strong driver of growth in addition to continued growth through infrastructure expansion and tech innovations providing significant opportunity for both manufacturers and healthcare providers.

• The report includes qualitative and quantitative data in the Extracorporeal Membrane Oxygenation Systems market across component, modality, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the Extracorporeal Membrane Oxygenation Systems market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Extracorporeal Membrane Oxygenation Systems market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Extracorporeal Membrane Oxygenation Systems market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 10 cover Extracorporeal Membrane Oxygenation Systems market segments by component, modality, application, end user, and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. They cover the market volume revenue forecast and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the Extracorporeal Membrane Oxygenation Systems market. Companies have been profiled on the basis of their key facts, business descriptions, products and services, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The Extracorporeal Membrane Oxygenation Systems market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the extracorporeal membrane oxygenation systems market are:

• In September 2024, Medtronic plc launched a new ECMO system called VitalFlow, which is a configurable one-system ECMO solution, built on simplicity and performance. The VitalFlow ECMO System bridges the gap between bedside care and intra-hospital transport, offering physicians and clinicians an easier, smarter ECMO experience.
• In January 2023, Extracorporeal Membrane Oxygenation auxiliary device of RocketMedical Co., Ltd. (Rocket Medical) is approved with conditions through emergency review by China NMPA. This product is the second domestic ECMO product granted approval. The product provides power and safety monitoring during extracorporeal circulation, and is used in combination with compatible disposable consumables for pulmonary support. The product is intended for adult patients with acute respiratory failure that is difficult to control by other treatments and where there is a foreseeable risk of continued deterioration or death.